6une 7 8 9 - ERA-EDTA · FC 04 - Bone disease in dialysis 09.30 - 10.45 Posters, coffee break and...
Transcript of 6une 7 8 9 - ERA-EDTA · FC 04 - Bone disease in dialysis 09.30 - 10.45 Posters, coffee break and...
Programme at a Glance - Sunday, June 7th, 2020
LEGENDA
Fluids and electrolytes, tubular transport,
physiology
Hereditary disorders, development, pregnancy,
paediatric nephrology
Glomerular diseasesand general
clinical nephrology
Chronic Kidney Disease: pathophysiology, epidemiology, prevention, progression, aging
End StageRenal Disease
and dialysis
Home therapies, peritoneal
dialysis
Transplantationand
immunology
Hypertension,diabetes,
vascular diseases
Acute Kidney Injuryand intensive care
nephrology
G1 G2A G2B F1 A1 A2 A3 A4 Presentation Theatre08.00 - 09.30 S 01 -
ERA-EDTA RegistryS 02 - Phosphate and FGF23
S 03 - Paediatric Nephrology
S 04 - The many facetsof hypoxia in CKD
FC 01 - Molecular insightin renal pathology
FC 02 - What should CKD patients eat?
FC 03 - Vascular access
FC 04 - Bone diseasein dialysis
09.30 - 10.45 Posters, coffee break and exhibition visitPACE-CME Boehringer Ingelheim/Lilly
Baxter Healthcare Fresenius Medical Care
NxStage Medical AstraZeneca
10.45 - 11.30 PL 1 - Sanjay Jain“Interface of molecular mechanisms, pathology and genetics of developmental kidney diseases”
11.30 - 11.45 Break11.45 - 13.15 S 05 -
Late Breaking Clinical Trials
S 06 -The many faces of monoclonal gammopathy of undetermined significance
S 07 - Improving outcomes in DKD
S 08 - Redefining the ontology of kidney diseases using genomic analysis
S 09 - Brain and nervous system in CKD
FC 05 - Delivery of dialysis: a holistic approach
FC 06 - The next generation of transplant therapeutical approaches
FC 07 - Managing hypertension
13.15 - 14.45 Fresenius Medical Care
Baxter Healthcare Charité-Vifor Fresenius Medical Care Renal Pharma
Novo Nordisk Amgen Europe MundiPharma Sanofi Genzyme Retrophin 13.15-14.00
15.00 - 16.30 S 10 - ASN Highlights
S 11 - ANCA-associated vasculitis
S 12 - Blood pressure targets
S 13 - Precision medicine for the sensitized transplant recipient
FC 08 - Protein energy wasting and inflammation
FC 09 - Novel molecular mechanisms of diabetic nephropathy
FC 10 - Clinical CKD
FC 11 - Improving outcome in dialysis patients
16.30 - 17.00 Posters, coffee break and exhibition visit17.00 - 18.30 S 14 -
Basic immunology and pathology
S 15 - Primary glomerulonephritides
S 16 - Salt and disease: a changing scenario / Sodium: where is it? How does it harm? How could we intervene?
S 17 -Start dialysis? Stop dialysis? - Challenging conversations
FC 12 - Genetics in kidney disease: unravelling complex interactions
FC 13 - Clinical nephrology: predicting outcome
FC 14 - AKI: still difficult to define
FC 15 - Novel discoveries in CKD pathophysiology
ADV - mm 297x40 + 3 mm bleed - PDF/JPGProgramme at a glance 6 7 8 9June
How to use this file...
Click on the dateor arrow to view
the summary table related to a specific day
Click on the LINK barre to view the details
of a specific session within the Virtual
Meeting Programme
Click on the ERA-EDTA logoto go backto the home page.
Click on theVirtual Meeting logoto visit theCongress webpage
TRAC
KS Fluids and electrolytes, tubular transport, physiology
Hereditary disorders, development, pregnancy,
paediatric nephrology
Glomerular diseasesand general
clinical nephrology
Chronic Kidney Disease: pathophysiology, epidemiology, prevention, progression, aging
End StageRenal Disease
and dialysisHome therapies, peritoneal
dialysisTransplantation
andimmunology
Hypertension,diabetes,
vascular diseases
Acute Kidney Injuryand intensive care
nephrology
Programme at a Glance - Saturday, June 6, 2020
CEPD and Practical Courses DayGold Plenary Silver Plenary Space 1-2 Space 3-4 Red 1-2 Brown 1-2 Brown 3 Blue 1-2 Yellow 1-2-3
08:45 - 12:25 PC 1Renal molecular pathology
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 0 8 2
CEPD 1Primary & Secondary glomerulo-nephritis, vasculitis, autoimmune diseasesh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 3 1
CEPD 2Hypertension, diabetes, cardiovascular diseases in CKD
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 3 2
CEPD 3CKD and bone mineral disorders in CKD
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 3 3
CEPD 4Onconephrology
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 3 4
PC 2Vascular access
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 5 112:25 - 13:00 Lunch break13:00 - 16:40 CEPD 5
Haemo- and peritoneal dialysish t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 3 5
CEPD 6Kidney transplantation
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 3 6
CEPD 7Acute kidney injury
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 3 7
CEPD 8Electrolytes and urolithiasish t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 3 8
CEPD 9Nephropathology
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 3 9
PC 2Vascular access (repeated)h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 5 1
Gold Plenary Silver Plenary Space 1-2 Space 3-4 Red 1-2 Brown 1-2 Brown 3 Blue 1-2 Yellow 1-2-307:30 - 08:30 ISS 0.1
New Progress of Adsorption Therapy - Jafron Medicalh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 1 0 8
08:00 - 08:30
17:00-18:00 Welcome Ceremony + LectureN. Watts“Sustainable healthcare”h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 4 0
CE
PD
PR
OG
RA
MM
EC
ON
GR
ES
S P
RO
GR
AM
ME
https://www.era-edta.org/en/virtual-meeting/#!contentsessions/46467
Programme at a Glance - Sunday, June 7, 2020
TRAC
KS Fluids and electrolytes, tubular transport, physiology
Hereditary disorders, development, pregnancy,
paediatric nephrology
Glomerular diseasesand general
clinical nephrology
Chronic Kidney Disease: pathophysiology, epidemiology, prevention, progression, aging
End StageRenal Disease
and dialysisHome therapies, peritoneal
dialysisTransplantation
andimmunology
Hypertension,diabetes,
vascular diseases
Acute Kidney Injuryand intensive care
nephrology
Gold Plenary Silver Plenary Space 1-2 Space 3-4 Red 1-2 Brown 1-2 Brown 3 Blue 1-2 Yellow 1-2-308:00 - 09:30 S 01
Medicine in the digital age
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 0 9 1
S 02ADPKD – tolvaptan and beyondh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 0 9 2
S 03The inflammatory pathway in CKD: treatments at last?h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 0 9 3
S 04ERA-EDTA Registry
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 0 9 4
FC 01Home dialysis (ML A. Wiecek)h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 7 4
FC 02Novel aspects of nephrolithiasis h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 8 2
FC 03Prevention of AKI
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 9 3
FC 04Basic science in diabetes
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 9 409:30 - 10:45 Posters, coffee break and exhibition visit
ISS 1.1Impacting cardiovascular and kidney protection in CKD: The evolving role of SGLT2iPACE CME - Boheringer Ingelheim/Lillyh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 2 0 9
ISS 1.2Expert approaches to management across the CKD-MBD continuumVifor Fresenius Medical Care Renal Pharmah t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 0 9 1
ISS 1.3Innovative endpoints for glomerular diseasesRetrophin
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 1 0 1
ISS 1.4K+: Recurrence, Restriction and FluctuationChange IME - AstraZenecah t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 0 8 9
10:45 - 11:30 PL 1A. Levey - Chronic kidney dise-ase: two decades of progress and challenges for the futureh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 4 9
11:30 - 11:45 Break11:45 - 13:15 S 05
Late breaking clinical trials
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 0 9 5
S 06Advanced renal MRI - the non-invasive renal biopsy in 2020h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 0 9 6
S 07Refocussing clinical research in CKD
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 0 9 7
S 08Towards more home- and self-care
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 0 9 8
S 09The AKI - AKD - CKD continuum
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 0 9 9
FC 05Clinical outcomes in transplantation 1 (ML R. Hellemans)h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 8 4
FC 06Hypertension and CKD (ML P. Sarafidis)
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 7 8
FC 07Molecular nephrology (ML B. Dekel)
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 7 9
FC 08Malnutrition in dialysis
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 9 513:30 - 14:45 ISS 1.5
Optimising RAASi therapy through long-term potas-sium control – opportunities for improved outcomesMedEd Global Solutions - Vifor Pharmah t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 0 9 4
ISS 1.6Dialysis in times of Pandemics: Challenges, Solutions and Lessons Learnt for the FutureFresenius Medical Care
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 2 1 3
ISS 1.7Improving diabetic kidney disease outcomes: A novel role for GLP-1 receptor agonistsNovo Nordisk
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 6 4 6 7
ISS 1.8Understanding the Relationship Between the Mineralocorticoid Receptor and Chronic Kidney Disease in Type 2 DiabetesBayerh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 6 4 6 8
ISS 1.9Pushing the boundaries of Fabry disease: new insights into diagnosis, immunogeni-city and long-term dataSanofi Genzyme
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 0 8 615:00 - 16:30 S 10
ASN Highlights
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 0 0
S 11Green health care in practice
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 0 1
S 12Paediatric nephrology
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 0 2
S 13How to manage maintenance anti-rejection treatment in the pre-sence of relevant co-morbidities?h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 0 3
FC 09Anaemia management in CKD (ML T. Drueke)
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 8 0
FC 10Clinical nephrology 1(ML G. Gambaro)
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 7 3
FC 11 - Prognosis in haemodialysis(ML V. Jha)
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 9 0
FC 12Exercise in CKD(ML N. Clyne)
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 8 1
FC 13Bone disease in dialysis
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 9 616:30 - 17:00 Posters, coffee break and exhibition visit17:00 - 18:30 S 14
Combatting kidney disease in Europe: role of European Kidney Health Alliance (EKHA)h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 0 4
S 15The diversified world of nephrology: what the nephrolo-gists do and how renal care is organised in different countriesh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 0 5
S 16Novel tools and target in renal fibrosis
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 0 6
S 17The uraemic syndrome in 2020
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 0 7
FC 14Glomerulonephritis 1 (ML Y. Caliskan + ML G. Moroni)
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 6 1 8 9
FC 15Aspects of CKD pathophysiology 1 (ML T. Johnson)
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 7 6
FC 16Cardiovascular diseases in dialysis
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 9 7
FC 17Novelties in cystic disease
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 9 8
SS 1Present situation on COVID-19 in Europe, globally and in nephrology
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 6 2 6 0
https://www.era-edta.org/en/virtual-meeting/#!contentsessions/46467
ISS 1.7Improving diabetic kidney disease outcomes: A novel role for GLP-1 receptor agonistsNovo Nordisk
Programme at a Glance - Monday, June 8, 2020
TRAC
KS Fluids and electrolytes, tubular transport, physiology
Hereditary disorders, development, pregnancy,
paediatric nephrology
Glomerular diseasesand general
clinical nephrology
Chronic Kidney Disease: pathophysiology, epidemiology, prevention, progression, aging
End StageRenal Disease
and dialysisHome therapies, peritoneal
dialysisTransplantation
andimmunology
Hypertension,diabetes,
vascular diseases
Acute Kidney Injuryand intensive care
nephrology
Gold Plenary Silver Plenary Space 1-2 Space 3-4 Red 1-2 Brown 1-2 Brown 3 Blue 1-2 Yellow 1-2-308:00 - 09:30 S 18
Big data and artificial intelligence in renal care
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 0 8
S 19Anaemia treatment in CKD: a changing scenario
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 0 9
S 20Novel diagnostics and treatments for inherited kidney diseases
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 1 0
S 21Ageing kidney and its implications
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 1 1
S 22Sympathetic overactivity as a major trigger of cardiovascular and renal outcomes in CKDh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 1 2
S 23Dietary approaches in CKD: promoting quality over quantify
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 1 3
FC 18Glomerulonephritis 2 (ML P. Ronco)
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 6 1 8 8
FC 19Clinical outcomes in transplantation 2
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 9 909:30 - 10:45 Posters, coffee break and exhibition visit ERA-EDTA
General Assembly
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 6 2 5 9
ISS 2.1Targeting the cause of ANCA Associated Vasculitis - Needs and OutcomesVifor Pharma
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 1 0 0
ISS 2.2Beyond the kidney: Unexpected causes of renal diseaseTakeda
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 0 9 0
ISS 2.3Clinical implications of Calcium-Sensing Receptor activationAmgen
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 0 8 5
ISS 2.4Another kidney stone referral - or a warning of imminent renal failure? How to spot the metabolic diseases that can cause sudden progression to ESRDAlnylam Pharmaceuticalsh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 1 1 3
ISS 2.5Cardiorenal cross-talk in diabetes: The preventive challenge in DKD for GLP-1 raPACE CME - Novo Nordiskh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 2 1 0
10:45 - 11:30 PL 2P. Romagnani - AKI, CKD and cancer: the costs of kidney repairh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 5 0
11:30 - 11:45 Break11:45 - 13:15 S 24
Systemic diseases and the kidney
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 1 4
S 25Everyday issues during haemodialysis
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 1 5
S 26Newer outcomes and strate-gies for implementing clinical trials in kidney transplantationh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 1 6
S 27Current aspects of AKI prevention and treatment
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 1 7
S 28Progress in osteodistrophy and pathways to arterial da-mage and calcification in CKDh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 1 8
FC 20Clinical nephrology 2 (ML J. Fox)
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 9 1
FC 21Aspects of CKD pathophysiology 2 (ML C. Ferro)h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 8 6
FC 22Health services for renal patients (ML C. Tomson)
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 7 7
FC 23Genetics in nephrology (ML A. Fornoni)
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 6 1 9 013:30 - 14:45 ISS 2.6
Anaemia of CKD: challenges, underlying mechanisms, and future perspectivesAstellash t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 2 1 1
ISS 2.7Iron deficiency beyond anaemia in kidney and heart disease - revisiting the cardiorenal syndromeMedEd Global Solutions - Vifor Fresenius Medical Care Renal Pharmah t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 0 9 5
ISS 2.8Clinical Conundrums in aTypical HUSAlexion Pharma
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 1 0 2
ISS 2.9Genetic Kidney Disease: From innovative diagnosis to new therapeutic targetsSanofi Genzyme
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 0 8 7
ISS 2.10SGLT2 inhibition in CKD: Our chance to make a differenceChange IME - AstraZenecah t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 7 1 0 3
15:00 - 16:30 S 29Expanding the patient’s voice in nephrology with patient outcome measuresh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 1 9
S 30Mechanisms on CKD progression
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 2 0
S 31PD strategies and outcomes
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 2 1
S 32Wasting in CKD: targeting the muscle
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 2 2
S 33Genetics in kidney disease
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 2 3
FC 24Glomerulonephritis 3(ML J. Floege)
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 7 5
FC 25CKD and nutrition (ML P. Molina)
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 9 2
FC 26Clinical diabetic nephropathy (ML K. Turkmen)
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 8 7
FC 27Revisiting the bone in CKD
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 6 0 0 016:30 - 17:00 Posters, coffee break and exhibition visit17:00 - 18:30 S 34
The hypertension spectrum in CKD: pathophysiology and risk
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 2 4
S 35Environmental threats to kidney health
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 2 5
S 36Sodium and human disease
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 2 6
S 37Electrolytes and acid-base for the future
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 2 7
FC 28Nephropathology insights (ML E. McQuarries)
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 8 9
FC 29Experimental AKI (ML M. Nangaku)
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 8 8
FC 30CKD epidemiology (ML G. Parati)
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 8 5
FC 31Paediatric nephrology (ML F. Emma)
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 7 2
SS 2Acute kidney injury, dialysis and transplantation in patients tested COVID-19 positiveh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 6 2 6 1
https://www.era-edta.org/en/virtual-meeting/#!contentsessions/46467
Programme at a Glance - Tuesday, June 9, 2020
TRAC
KS Fluids and electrolytes, tubular transport, physiology
Hereditary disorders, development, pregnancy,
paediatric nephrology
Glomerular diseasesand general
clinical nephrology
Chronic Kidney Disease: pathophysiology, epidemiology, prevention, progression, aging
End StageRenal Disease
and dialysisHome therapies, peritoneal
dialysisTransplantation
andimmunology
Hypertension,diabetes,
vascular diseases
Acute Kidney Injuryand intensive care
nephrology
Gold Plenary Silver Plenary Space 1-2 Space 3-4 Red 1-2 Brown 1-2 Brown 3 Blue 1-2 Yellow 1-2-308:30 - 10:00 S 38
Cardiovascular and renal protection - effects of SGLT2 inhibitors and GLP-1 receptor agonists in people with CKD and type 2 diabetesh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 2 8
S 39New immune therapies and onconephrology
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 2 9
S 40Cognitive impairment in CKD
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 3 0
FC 32Experimental transplantation (ML M. Essig)
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 9 8 3
FC 33Extracorporeal treatment of ESKD
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 6 0 0 1
FC 34Outcome after AKI
h t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 6 0 0 210:00 - 10:15 Break10:15 - 11:00 PL 3
B. StaelsCircadian control of metabolism and inflammation and pathological consequences of clock perturbationsh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 5 1 4 8
11:15 - 12:45 SS 3Nephrology Pearlsh t t p s : / / w w w . e r a - e d t a . o r g / e n / v i r t u a l - m e e t i n g / # ! c o n t e n t s e s s i o n s / 4 6 2 6 9
https://www.era-edta.org/en/virtual-meeting/#!contentsessions/46467
www.era-edta.org